What is Turn Therapeutics?
Turn Therapeutics operates as a sophisticated research and development entity dedicated to the creation of best-in-class products for infection control, skin disease, and advanced wound care. By focusing on proprietary technologies that address unmet clinical needs, the company has established itself as a vital partner for world-leading healthcare institutions. Its operational model emphasizes a concept-to-approval approach, ensuring that scientific innovation is systematically translated into practical, life-saving medical applications. The firm's market position is defined by its ability to bridge the gap between laboratory-scale discovery and large-scale clinical implementation, making it a key player in the evolution of modern wound management and dermatological health.
How much funding has Turn Therapeutics raised?
Turn Therapeutics has raised a total of $101.7M across 2 funding rounds:
Other Financing Round
$75M
Debt
$25M
Other Financing Round (2024): $75M with participation from Global Emerging Markets
Debt (2026): $25M led by Avenue Capital Group
Key Investors in Turn Therapeutics
Global Emerging Markets
Global Emerging Markets is a multi-billion dollar alternative investment group specializing in diverse vehicles including private investments in public equities and select venture opportunities.
Avenue Capital Group
Avenue Capital Group is a multinational investment firm with a deep focus on distressed securities and private equity, providing strategic financial support to growing enterprises.
What's next for Turn Therapeutics?
With the recent infusion of capital, Turn Therapeutics is expected to prioritize the expansion of its clinical pipeline and the optimization of its manufacturing capabilities. The strategic focus will likely shift toward accelerating regulatory approval processes and broadening the adoption of its proprietary technologies across global healthcare networks. As the company matures, the emphasis will remain on maintaining its competitive edge through rigorous scientific validation and the pursuit of novel therapeutic modalities. Investors and industry stakeholders will be closely monitoring the firm's ability to convert this recent financing into tangible clinical outcomes and sustained market growth, particularly as it navigates the complexities of the global healthcare regulatory environment.
See full Turn Therapeutics company page
